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Lipoic acid (LA) is a natural compound, chem-
ically it is (R)-5-(1,2-dithiolan-3-yl)pentanoic acid
(1-3). Lipoic acid is predominantly a lipophilic mol-
ecule having an amphipathic character due to its car-
boxylic acid group attached to the ring structure. In
humans, LA is synthetized by the liver and other tis-
sues with high metabolic activity: heart, kidney.
High concentrations of this acid are found in animal
tissues with extensive metabolic activity such as
heart, liver and kidney. LA is widely distributed in
both cellular membranes and cytosol. LA is easily
absorbed from the gastrointestinal tract, is able to
cross the blood-brain barrier, and does not exhibit
any serious side effects (4). 
LA contains an asymmetric carbon atom,
which results in two possible optical isomers (R and
S). Only the R-isomer is endogenously synthesized.
LA contains two thiol groups, which may be oxi-
dized or reduced. As with the thiol antioxidant - glu-
tathione, LA is part of a redox pair, being the oxi-
dized partner of the reduced form - dihydrolipoic
acid (DHLA), which also possesses biological activ-
ity. Both LA and DHLA are easily soluble (5).
The chemical reactivity of LA is mainly due to
its dithiolane ring. Therapeutic action of LA is based
on unique antioxidant properties of LA/DHLA sys-
tem, which possesses one of the lowest standard bio-
logical redox potential (6-10). Thus, DHLA is able
to reduce not only reactive oxygen species (ROS)
but also oxidized forms of other antioxidants. For
this reason, it is called an antioxidant of antioxidants
(5, 11). The reaction of LA with hydroxyl radical,
for example, yields lipoic acid cation radical, which
is transformed into LA by other antioxidants that
can be regenerated by DHLA. Exogenous LA can be
reduced to DHLA by several enzymes, including
mitochondrial lipoamide dehydrogenase, which uti-
lizes NADH, and cytoplasmic NADPH-dependent
reductases: glutathione reductase and thioredoxin
reductase (5).
Endogenously synthesized LA is covalently
bound to specific proteins, which function as cofac-
tors for mitochondrial dehydrogenase enzyme com-
plexes (12, 13). LA has long been known as a coen-
zyme of multienzymatic complexes catalyzing the
decarboxylation of α-ketoacids, but the present
investigations are focused on its antioxidative prop-
erties and its reduced form DHLA (13). Studies have
shown that both the oxidized and reduced forms of
lipoic acid are antioxidants. LA scavenges hydroxyl
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radicals, hypochlorous acid and singlet oxygen. It
may also exert antioxidant effects in biological sys-
tems through transitional metal chelation, resulting
in reduced ROS production. Both LA and DHLA
are also responsible for the regeneration of active
forms of other cellular antioxidants, including vita-
mins C and E (7). Dihydrolipoic acid has been
shown to have antioxidant but also pro-oxidant
properties in systems in which hydroxyl radical was
generated. Lipoic acid was initially included in the
vitamin B complex. However, at present, LA is not
considered to be a vitamin (14).
It is probable that LA/DHLA system plays a
significant role in the processes with sulfane sulfur,
since it is known from in vitro studies that DHLA
serves as a sulfane sulfur acceptor in rhodanese-cat-
alyzed reactions. Sulfane sulfur containing dihy-
drolipoic acid hydropersulfide, formed in this reac-
tion, releases sulfane sulfur in the form of hydrogen
sulfide (H2S) (15). Sulfane sulfur is a labile reactive
sulfur atom in the 0 or ñ1 oxidation state, covalent-
ly bound to another sulfur atom (15). Rhodanese
catalyzes sulfane sulfur transfer to different accep-
tors (15). Sulfane sulfur transfer to thiol groups of
receptor and enzymatic proteins leads to the forma-
tion of hydropersulfides and/or trisulfides that often
changes activity of these proteins. The role of sul-
fane sulfur in the formation of iron-sulfur center of
iron-sulfur proteins has also been suggested.
Other properties of lipoic acid, apart from the
antioxidant function, comprise: modulation of mito-
gen-activated protein kinase activity, reduction of
production of inflammatory mediators, lowering of
endothelin expression, effect on secondary messen-
gers of the nuclear factor β and peroxisome prolifer-
ator-activated receptors (PPAR) activation cascade,
and implication in the regulation of carbohydrate
and lipid metabolism (8, 16).
LA has some neuroprotective properties (8, 17,
18). The precise mechanism of its neuroprotective
effects remains unclear. It is known that it can inhib-
it microglial activation and caspase-related apoptot-
ic pathways (18).
Various studies have shown, that LA exerts
powerful anti-inflammatory and anti-oxidant effects
in vitro. Treatment of cultured monocytes with LA
inhibits lipopolysaccharide-mediated induction of
pro-inflammatory factors. LA, by virtue of its
antioxidant effect, has been shown to be beneficial
in many metabolic and vascular diseases (16).
Consistent with these effects, LA has been shown to
be protective in human diseases associated with
abnormal oxidative stress and energy metabolism
(13). A number of experimental as well as clinical
studies point to the usefulness of LA as a therapeu-
tic agent for such diverse conditions like atheroscle-
rosis, insulin resistance, neuropathy, neurodegener-
ative diseases and ischemia-reperfusion injury. LA
significantly improves diabetic neurovascular and
metabolic abnormalities, glycemic control and
improves glucose utilization by cells due to stimula-
tion of insulin-dependent Akt/PKB signaling path-
way (4).
LA is a medication recommended in many
countries in diabetic neuropathy. Also, it may play a
role in cardiovascular protection and as an antiin-
flammatory agent (19). It also improves allergic
inflammation (19). Studies have revealed that LA
effectively suppresses allergic inflammation in a
murine model of asthma by reducing the level of
reactive oxygen species. LA represents a potential
agent on the vascular endothelium. LA has also been
considered as a therapeutic agent candidate for the
treatment or prevention of pathologies associated
with an imbalance of oxidoreductive status, such as
neurodegeneration, ischemia-reperfusion, hepatic
disorders, and asthma (19). Studies currently in
progress support its use in the treatment of other dis-
eases (autoimmune diseases, cancer, AIDS).
LA can easily cross bloodñbrain barrier (18).
Thus, its use has been proposed in the treatment of
neural disorders. LA has been shown to have a vari-
ety of properties which can interfere with the patho-
genesis or progression of Alzheimer disease (17,
20). 
All these features make lipoic acid a very
promising drug. Therefore, we first posed a question
whether LA has anti-inflammatory activity in ani-
mals and what is the mechanism of action of anti-
inflammatory effect. To answer this question, we
administered LA to mice and then we assayed S*
and effects of LA on inflammatory parameters
(infiltration of neutrophils and vascular permeabili-
ty) during zymosan peritonitis. As a reference drug
for anti-inflammatory activity we have used
indometacin ñ a nonselective COX inhibitor that is
effective in many murine models of inflammation
(21).
EXPERIMENTAL
Animals
The experiments were carried out on male albi-
no Swiss mice (body weight 20-26 g). The animals
were housed in constant temperature facilities
exposed to 12 : 12 h light-dark cycle and maintained
on a standard pellet diet, tap water was given ad libi-
tum. Control and experimental groups consisted of
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six to eight animals each. The investigated com-
pounds were administered intraperitoneally (i.p.) as
a suspension in 1% Tween 80.
Methods
Infiltration of neutrophils in a model of zymosan-
induced peritonitis
In a model of zymosan-induced peritonitis,
zymosan A was freshly prepared (2 mg/mL) in ster-
ile 0.9% saline (22). Thirty minutes after the s.c.
injection of the LA - zymosan A (0.5 mL) was
injected i.p. LA was suspended in 1% Tween 80 and
pitched in ultrasonic cleaner. A dose of 50 mg/kg
b.w. was chosen for test, because it is frequently
used dose of LA in different studies. Animals were
killed by decapitation after 4 h. The peritoneal cavi-
ty was lavaged with 1.5 mL of saline and after 30 s
of gentle manual massage the exudate was retrieved.
Cells were counted with the automatic cell counter
(Countess, Invitrogen) following staining with
Turkís solution. The control group was given s.c.
1% Tween 80 in a volume of 0.25 mL (23 ). The
zymosan group, 30 min prior to zymosan, was given
s.c. 1% Tween 80 in a volume of 0.25 mL.
Vascular permeability in a model of zymosan-
induced peritonitis 
LA suspended in 1% Tween 80 was injected
s.c. in doses 10, 30, 50, 100 mg/kg b.w. Then, after
30 min, Evans blue suspended in saline (10 mg/mL)
was injected i.v. into the caudal vein (0.2 mL/mouse)
immediately followed by i.p. injection of zymosan
A. Thirty minutes later, the animals were killed and
their peritoneal cavities were lavaged with 1.5 mL of
saline as described above. The lavage fluid was cen-
trifuges and the absorbance in the supernatant was
measured at 620 nm (23). The intensity of early vas-
cular permeability was measured at 30 min of
zymosan-induced peritonitis. The control group, 30
min prior to zymosan, was given s.c. 1% Tween 80
in a volume of 0.25 mL (23). Indomethacin injected
s.c. in a dose of 10 mg/kg b.w. was used as a refer-
ence compound. 
Determination of sulfane sulfur level in the peri-
toneal exudates
The level of S* in homogenates was deter-
mined by cold cyanolysis. To 100 µL of peritoneal
Figure 2. Vascular permeability changes during zymosan-induced peritonitis in mice. The mean ± SD of absorbance, n = 6ñ8. Students t-
test, differences significant vs. control group - zymosan-induced peritonitis: * p < 0.05; ** p < 0.01. Groups: IND10 ñ indomethacin 10
mg/kg b.w.; LA10 ñ LA 10 mg/kg b.w.; LA 30 ñ LA 30 mg/kg b.w.; LA 50 ñ LA 50 mg/kg b.w.; LA 100 ñ LA 100 mg/kg b.w.
Figure 1. Infiltration of neutrophils changes during zymosan-
induced peritonitis in mice. The mean ± SD of count of neu-
trophils, n = 6ñ8. Student t-test, *differences significant for con-
trol group vs. zymosan: *** p < 0.001, ∆ - differences significant
vs. zymosan, groups: LA50 ñ LA 50 mg/kg b.w.; ZYM ñ
zymosan, control ñ Tween 80
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exudates, 80 µL of 1 M amonia, 720 µL of distilled
water and 100 µL of 0.5 M KCN were added. The
samples were incubated at room temperature for 45
min. Then, 20 µL of 38% formaldehyde and 200 µL
of Goldsteinís reagent [Fe(NO)3 + HNO3 + H2O]
were added. After centrifugation at 12,000 ◊ g for
10 min, the absorbance at 460 nm was determined.
A standard curve was prepared with 1 mM KSCN
(6). The control group was given s.c. 1% Tween 80
in a volume of 0.25 mL. The zymosan group, 30 min
prior to zymosan, was given s.c. 1% Tween 80 in a
volume of 0.25 mL.
Statistical analysis
The statistical significance was calculated
using Studentís t-test. Differences were considered
statistically significant at p ≤ 0.05.
RESULTS 
Effects of lipoic acid on infiltration of neutrophils
during zymosan peritonitis 
The intensity of early infiltration of neutrophils
measured at 30 min of zymosan peritonitis was signif-
icantly inhibited in LA-group compared to the control
group (Fig. 1). LA decreased by 78% count of neu-
trophils in a model of zymosan-induced peritonitis.
Effects of lipoic acid on vascular permeability
during zymosan peritonitis 
The study showed that the intensity of early
vascular permeability was significantly inhibited in
groups received lipoic acid (LA100, LA50, LA30
groups) by 34.64-36.26% compared to the control
group (Fig. 2). LA given at a dose of 10 mg/kg b.w.
had no significant influence on vascular permeabili-
ty. As a reference compound indomethacin was used
at a dose of 10 mg/kg b.w. (IND10). The effect of
reducing the vascular permeability of LA was not
greater than that of indomethacin.
Effects of lipoic acid on sulfane sulfur level in the
peritoneal exudates
LA administered at a dose 50 mg/kg b.w.,
increased of sulfane sulfur level in the peritoneal
exudates by 11.5 times compared to the control
group (Fig. 3). Zymosan increased the sulfane sulfur
level in the peritoneal exudates by 4.5 times com-
pared to the control group. However, after the
administration of LA, sulfane sulfur increase was
2.5 times greater in comparison to zymosan.
DISCUSSION AND CONCLUSION
LA/DHLA system is one of the most important
redox systems in human body. Exogenous LA can
be reduced to DHLA by several enzymes so that LA
and DHLA are in dynamic equilibrium, and can
replace each other. In this paper, we tested only LA
because it is now the drug with well-established
therapeutic use. The aim of the current study was to
evaluate of anti-inflammatory activity of LA. For
this purpose we used zymosan-induced peritonitis in
mice. Murine zymosan peritonitis was described as
a suitable model of acute inflammation, character-
ized by vascular changes and mediator production
leading to leukocyte accumulation at the inflamma-
tory focus (22, 23). Two major events are critical for
development of zymosan peritonitis, namely: the
early increase in vascular permeability (< 1 h) and
the infiltration of neutrophils into the peritoneum
that follows after some hours (23). The mechanisms
operating during the above stages have been investi-
gated and these studies revealed that early vascular
permeability depends mostly on cysteinyl-
leukotrienes released by resident peritoneal
macrophages and, to lesser extent, on mast cell his-
tamine and prostaglandins (PGE2, prostacyclin) of
multiple cellular origin (23).
The studies focused on two major events lead-
ing to the onset of inflammation ñ the early increase
Figure 3. Sulfane sulfur level in the peritoneal exudates. The mean
± SD of sulfane sulfur level, n = 6ñ8. Student t-test, differences
significant vs. control group :* p < 0.05, ** p < 0.01. Groups:
LA50 ñ LA 50 mg/kg b.w.; ZYM ñ zymosan, ∆ - differences sig-
nificant vs. zymosan, control ñ Tween 80
Anti-inflammatory activity of lipoic acid in mice peritonitis model 903
in vascular permeability and neutrophil infiltration
into peritoneum. The study showed that LA has
demonstrated anti-inflammatory activity in both
tests. In the study of cellular infiltration, it signifi-
cantly limited the migration of leukocytes to the site
of inflammation, which was the peritoneum. The
statistical analysis showed that LA significantly
reduced the vascular permeability.
To explain the mechanism for anti-inflamma-
tory activity of lipoic acid, sulfane sulfur level in the
peritoneal exudates was determined and it was
found that LA increased this level. 
A number of both in vivo and in vitro studies
provide evidence that the gaseous transmitter (H2S)
plays an important role as a modulator of inflamma-
tory processes in various tissues, by acting on mul-
tiple targets. Recent data also suggest that H2S may
contribute to inflammatory processes. Several recent
reports provide evidence suggesting a role for H2S in
inflammation. H2S can scavenge peroxynitrite and
can interfere with the ability of neutrophils, through
hypochlorous acid, to kill microbes and other cells.
It can also induce neutrophil apoptosis, thereby con-
tributing to resolution of inflammatory reactions
(24). 
The precise sites and mechanisms of action of
H2S as an inflammatory mediator are not well estab-
lished, although the existing data indicate diverse
targets. It directly stimulates capsaicin-sensitive pri-
mary afferent neurons in the rat urinary bladder via
an unknown molecular interaction. Some anti-
inflammatory and anti-nociceptive effects of H2S
seem to be mediated via activation of ATPsensitive
K+ channels (KATP), as these effects were effec-
tively prevented by glibenclamide, a KATP channel
blocker. Other anti-inflammatory effects of H2S
occur via up-regulation of heme oxygenase-1 and
CO production, leading to inhibition of the nuclear
factor κB (NF-κB) pathway and down-regulation of
inducible NO synthase (iNOS) expression and NO
production by inflammatory stimuli (24-26).
In summary, the results of the present study
have demonstrated anti-inflammatory activity of
lipoic acid in mice peritonitis model. LA has
decreased the count of neutrophils in a model of
zymosan-induced peritonitis and significantly inhib-
ited early vascular permeability compared to control
group. LA serves as a sulfane sulfur acceptor and
releases sulfane sulfur in the form of hydrogen sul-
fide (H2S), which is probably responsible for its
anti-inflammatory activity. Hydrogen sulfide
inhibits the release of proinflammatory cytokines
(IL-1β, IL-6, TNF-α), NOï oraz PGE2. These effects
depend on the dose and rate of release of hydrogen
sulfide at various stages of infection. The most effi-
cient way affects low concentrations of H2S released
slowly for a long time. It is possible that in this way
hydrogen sulfide is released, which would explain
the anti-inflammatory action of lipoic acid. In the
future research, the levels of cytokines and
eicosanoids as a pro-inflammatory mediators should
be evaluated.
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